Eli Lilly and Company (NYSE:LLY) Stock Gets Price Target Bump from Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised Eli Lilly’s price target to $1,600 from $1,500 and maintained an “outperform” rating, implying 12.54% upside from the prior close.
• Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48 exceeding estimates of $5.68. Mounjaro and Zepbound sales drove growth, while the company raised its 2026 revenue forecast to $91 billion-$92 billion.
• Shares rose 3.5% to $1,421.69, although analysts’ consensus remains “Moderate Buy” with a $1,374.46 target. Key risks include lower realized prices, potential reductions in weight-loss-drug coverage and the stock’s elevated valuation.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective boosted by research analysts at Royal Bank Of Canada from $1,500.00 to $1,600.00 in a report released on Friday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's target price points to a potential upside of 12.54% from the stock's previous close.

Several other equities analysts have also recently commented on LLY. Argus boosted their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a research report on Friday. Leerink Partners raised their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 21st. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $1,374.46.

Eli Lilly and Company Trading Up 3.5%

Shares of NYSE:LLY traded up $47.99 during trading on Friday, reaching $1,421.69. The stock had a trading volume of 1,916,131 shares, compared to its average volume of 2,927,632. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The firm's fifty day moving average is $1,194.34 and its 200 day moving average is $1,090.89. The stock has a market cap of $1.34 trillion, a price-to-earnings ratio of 47.67, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.68 by $1.80. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same period in the prior year, the business earned $7.02 EPS. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. Corporate insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp boosted its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after acquiring an additional 400,538 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted earnings per share of $7.48 exceeded analyst expectations. Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion. Reuters: Eli Lilly lifts revenue outlook
• Positive Sentiment: Mounjaro sales climbed 65% to $10.7 billion and Zepbound sales increased 49% to $5.35 billion. Combined tirzepatide sales surpassed $16 billion, reinforcing Lilly’s leadership in the rapidly expanding GLP-1 diabetes and weight-loss market. Pharmaceutical Technology: Eli Lilly’s tirzepatide outperforms
• Positive Sentiment: Management highlighted expanding Medicare access, rising demand from middle-income consumers and encouraging traction for Foundayo. Positive Phase 3 results for experimental obesity and diabetes drug retatrutide also strengthened expectations for Lilly’s future pipeline and increased competitive pressure on Novo Nordisk. Zacks: LLY Q3 earnings call highlights
• Neutral Sentiment: Lilly’s pipeline is broadening beyond GLP-1 therapies, with cancer, immunology and neuroscience products viewed as potential additional growth drivers. However, the stock’s strong rally has raised the performance bar and leaves investors focused on whether growth can remain strong at its current valuation. Yahoo Finance: Cancer drugs as future growth drivers
• Negative Sentiment: Realized prices fell about 15%, although a 53% volume increase more than offset the decline. Results also benefited from roughly $900 million in favorable items, while acquisition-related charges reduced earnings. Potential employer cutbacks in weight-loss-drug coverage and ongoing pricing pressure remain risks. Motley Fool: Eli Lilly sells more at lower prices

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.